Access cutting-edge minimal change disease (mcd) treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Los Angeles location
Preparing your pre-screening questions…
Access minimal change disease (mcd) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related minimal change disease (mcd) treatment provided free
Check if you qualify for this minimal change disease (mcd) clinical trial in Los Angeles, CA
No-Cost Study Care
Local to Los Angeles
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients. In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium. Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.
Sponsor: University of Michigan
Yes, this clinical trial (NCT01209000) has an active research site in Los Angeles, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for minimal change disease (mcd) treatment options in Los Angeles, CA, this clinical trial (NCT01209000) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced minimal change disease (mcd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all minimal change disease (mcd) clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in Los Angeles — not just this study.
Browse Heart Attack Trials in Los Angeles →